CVS vs RPRX · P/E 16, rev $106.10B vs P/E 15, rev $1.30B
CVS Health Corp (CVS) versus Royalty Pharma Plc (RPRX) — a side-by-side from cached financials, not a winner call.
CVS Health Corp (CVS) is a healthcare plans company listed on US.
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
Latest reported CVS revenue for 2026-06-30 was $106.10B. Net income was $2.98B. Revenue was up 5.6% from 2026-03-31 to 2026-06-30. CVS currently screens at market cap $86.20B and trailing P/E 16.3.
Latest reported RPRX revenue for 2026-06-30 was $1.30B. Net income was $312.6M. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
CVS currently screens at market cap $86.20B and trailing P/E 16.3. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
Not investment advice. Open the CVS and RPRX stock pages for the full models.
Not investment advice.